Treatment for estrogen positive women with breast cancer has been adjuvant treatment of Tamoxifen for 10 years. According to a recent study, there is definitely a benefit of this adjuvant therapy and even recommendations of continuing the Tamoxofen for an extra five years. It is found that the benefits of extending the Tamoxifen far outweighs the risks of the extended use.
There are ongoing clinical trials comparing the 5 year and 10 year use of aromatase inhibitors. Stage really matters when looking at this data and outcome as well as looking at the risks, symptoms, and quality of life. Future research to help improve the understanding of this information and although we have been treating, we need a larger group in order to see if the efficacy of the 10 years may help those remaining questions as to the longer use of the drug.
Just a little food for thought. Great
Disclaimer: This website is for informational purposes only and is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of any medical institution.